Vesalius Biocapital, a Luxembourg-based biotech venture firm, has obtained over $72.7 million in the first closing of its third fund, VBC III, bringing it closer to its target of approximately $167.8 million. The fund will invest in 10 to 15 late-stage European companies focused in the areas of medtech, diagnostics, drugs and digital health.
Vesalius Biocapital closes 3rd fund at more than $72.7M
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.